Humanized Xenograft Models Available at Reaction Biology
Set up:
To engineer the humanized MOLM-13 acute myeloid leukemia model, PBMCs were isolated from buffy coats from four human blood donors. T cells were isolated from PBMC fractions of each donor, and purity was determined using flow cytometry (Figure 2). NOG and NOD-SCID mouse strains were used for the study. On days -3 and -2, mice were pretreated with cyclophosphamide. On day 0, MOLM-13_Luc+ tumor cells were injected intravenously into all mice. Isolated T cells from donors 1 & 2 were injected intravenously into NOG mice on day 8. Isolated T cells from donors 3 & 4 were injected in NOD-SCID mice on day 15.
Goal:
Humanized MOLM-13 acute myeloid leukemia model is suitable for the investigation of bi-specific engagers using isolated T or NK cells from PBMCs of whole blood donors.
Results:
Figure 1: Tumor growth of the MOLM13_Luc cells was monitored using an IVIS®Lumina III bioluminescence imaging system (PerkinElmer).
Addition of T cells did not influence the exponential MOLM-13_Luc tumor growth in NOG mice and only slightly retarded the growth in NOD-SCID mice.
T-Cell Purity Check
Figure 2: T cells are obtained with a high purity by negative selection from buffy coat derived PBMCs.